Nevirapine Shortage: What Providers and Prescribers Need to Know in 2026

As an HIV provider, you likely have patients who remain on nevirapine — either because they have been virologically suppressed on it for years, or because of cost and insurance considerations. While nevirapine is not in a formal FDA shortage as of 2026, the brand-name discontinuation and limited retail stocking of this specialty medication continue to create access challenges for some patients. This guide provides a clinical overview of the supply landscape and what prescribers should know.

Current Supply Status: No FDA Shortage, But Patchy Retail Availability

Nevirapine is produced by multiple generic manufacturers — Aurobindo Pharma, Camber Pharmaceuticals (Macleods), Mylan, and Apotex among others — so the national supply pipeline is robust. Neither the 200 mg immediate-release tablet nor the 400 mg extended-release tablet appears on the FDA's current drug shortage database.

That said, local retail pharmacy stocking remains inconsistent. Because nevirapine is no longer a preferred agent in DHHS, EACS, or WHO guidelines for treatment-naive adults and adolescents, demand has declined over the past decade. Some retail pharmacies, particularly in areas with lower HIV prevalence, do not routinely stock it. Specialty pharmacies remain the most reliable source.

Brand Discontinuation: Clinical Implications for Your Patients

Boehringer Ingelheim discontinued Viramune and Viramune XR as branded products. Patients previously receiving these products are now dispensed generics from one of several manufacturers. Clinically, the generics are bioequivalent to the originator. However, you may encounter patients reporting confusion about their medication (different pill size, color, or imprint) or expressing concern about efficacy. Counsel these patients that therapeutic equivalence is ensured through FDA bioequivalence standards.

Which Patients Are Still on Nevirapine in 2026?

Your nevirapine-experienced patients likely fall into one of these categories:

Long-term stable suppressors: Patients who started nevirapine years ago and remain virologically suppressed. Switching may not be clinically necessary, but access challenges may prompt a conversation.

Cost-driven patients: Nevirapine generic is among the least expensive HIV medications available. Patients without comprehensive insurance or on ADAP may be on it due to affordability.

Pediatric and perinatal patients: Nevirapine oral suspension remains in use for infants and young children for PMTCT and pediatric HIV management.

When to Consider Switching Away From Nevirapine

Clinical indications for switching a stable nevirapine patient include:

Persistent access difficulties — if a patient is repeatedly unable to fill nevirapine at their pharmacy

New comorbidities affecting tolerability (e.g., hepatic impairment) — nevirapine is contraindicated in Child-Pugh B/C

New drug interactions with high-risk CYP3A4-inducing medications added to the regimen

Patient preference — for improved tolerability, simplicity, or fixed-dose combination options

Insurance changes that make newer agents cost-neutral

38,912+ patients found their medications in stock

38K+

Find Nevirapine In Stock Today →

Switch Options: A Clinical Overview

For virologically suppressed patients who need to switch from nevirapine, options within the NNRTI class include rilpivirine (if VL baseline was <100,000 c/mL and no PPI use) and doravirine (no viral load restriction, no food requirement, fewer drug interactions). Switching to an integrase inhibitor backbone (dolutegravir, bictegravir, cabotegravir) is also well-supported by switch study data and may be preferable for patients with a history of NNRTI resistance mutations.

For switch-eligible patients, resistance testing should ideally be reviewed before a regimen change. Archived NNRTI resistance mutations (Y181C, K103N) are clinically relevant when selecting the next agent.

Monitoring Parameters for Patients Remaining on Nevirapine

Per prescribing information, intensive clinical and laboratory monitoring is essential during the first 18 weeks of nevirapine therapy. For established patients, ongoing hepatic function monitoring is appropriate — particularly if they develop new symptoms of liver toxicity. The FDA-labeled contraindication to initiating nevirapine in women with CD4>250 or men with CD4>400 applies only to initiation, not continuation of a suppressed, well-tolerated regimen.

Skip the calls, skip the stress.

Find Nevirapine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

How medfinder Supports Your Nevirapine Patients

When your patients call you because they can't find nevirapine at their pharmacy, medfinder can help resolve the issue quickly. medfinder calls pharmacies in the patient's area to locate which ones have the medication in stock, then texts the patient the results. Providers can learn more and refer patients at medfinder.com/providers.

See also our full provider guide: How to help your patients find nevirapine in stock.